Watson Pharmaceuticals Enters Agreement for Novartis’ Headache Treatments
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 33 (Table of Contents)
Published: 3 Feb-2003
DOI: 10.3833/pdr.v2003.i33.938 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Watson Pharmaceuticals agreed to acquire US rights to two product lines Fioricet® and Fiorinal® for tension headaches, from Novartis Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018